JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Strona główna・Stock List・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Closed

3.99 3.1

Buy Sell

Overview

Share price change

24h

Current

Min

3.96

Max

4.11

Key metrics
By Trading Economics
Income	-8.5M -35M
Employees	106
EBITDA	-11M -37M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+107.29% upside

Dividends
By Dow Jones
Next Earnings	12 maj 2026

Market Stats
By TradingEconomics
Market Cap	122M 286M
Previous open	0.89
Previous close	3.99

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.23 / 1.45 Support & Resistance

Zentalis Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank -2-

24 kwi 2026, 19:19 UTC

Acquisitions, Mergers, Takeovers

Intertek Group Rejects EQT's Revised Offer

26 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26 kwi 2026, 23:44 UTC

Earnings

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26 kwi 2026, 23:44 UTC

Earnings

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Gold Falls Amid Dollar's Strength -- Market Talk

26 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24 kwi 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Scoring the Cook Era -- Barrons.com

24 kwi 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

24 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:09 UTC

Earnings

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 kwi 2026, 19:48 UTC

Market Talk

Major News Events

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 kwi 2026, 19:22 UTC

Earnings

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 kwi 2026, 19:06 UTC

Earnings

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 kwi 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 kwi 2026, 18:30 UTC

Acquisitions, Mergers, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 kwi 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

Intertek Rejects Revised EQT Offer

24 kwi 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 kwi 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 kwi 2026, 17:42 UTC

Earnings

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 kwi 2026, 17:28 UTC

Earnings

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer Comparison

Price change

Zentalis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

107.29% upside

12 Months Forecast

Average 8.25 USD 107.29%

High 10 USD

Low 4 USD

Based on 5 Wall Street analysts offering 12 month price targets forZentalis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Zentalis Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.23 / 1.45Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.